Lamictal Tapering Guide
lamotrigine
Boxed Warning
Serious skin rashes including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), especially during initial titration. Increased risk of suicidal thoughts and behavior (anticonvulsant class warning).
Overview
Lamotrigine is an anticonvulsant approved for epilepsy (partial seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome) and maintenance treatment of bipolar I disorder. It is the only mood stabilizer with strong evidence for preventing bipolar depression.
25mg, 50mg, 100mg, 200mg
Tablets: 25mg, 100mg, 150mg, 200mg; Chewable/dispersible tablets: 2mg, 5mg, 25mg; Orally disintegrating tablets (ODT): 25mg, 50mg, 100mg, 200mg; Extended-release tablets (XR): 25mg, 50mg, 100mg, 200mg, 250mg, 300mg
Category C (risk cannot be ruled out)
Mechanism of Action
Blocks voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting release of excitatory neurotransmitters (primarily glutamate). May also modulate calcium channels and HCN channels. The anti-glutamate mechanism is thought to underlie its mood-stabilizing effects.
Taper Notes
Used as mood stabilizer. Must taper slowly — if stopped and restarted, must re-titrate from scratch due to SJS risk. Available in chewable/dispersible tablets.
Hyperbolic Tapering Guidance
Gradual taper essential. If a dose is missed for >5 days, re-titration from low dose is required due to serious rash risk (SJS). Chewable tablets allow fine dose adjustments.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Valproate significantly increases lamotrigine levels (~2x) by inhibiting glucuronidation — must halve lamotrigine dose
- Enzyme inducers (carbamazepine, phenytoin, phenobarbital, primidone, rifampin) decrease lamotrigine levels — dose adjustment needed
- Oral contraceptives (estrogen-containing) decrease lamotrigine levels by ~50% — dose adjustment needed during pill-free week
Food Interactions
- Food does not affect absorption
- No significant food interactions
Contraindications
- Known hypersensitivity to lamotrigine
Toxicity
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) — risk highest with rapid titration, concurrent valproate, and in children. Aseptic meningitis. Multiorgan hypersensitivity (DRESS). Suicidal ideation (anticonvulsant class warning).
Pharmacokinetics
ADME Profile
Rapidly and completely absorbed after oral administration. Bioavailability ~98%. Tmax ~1.4–4.8 hours. Food does not affect absorption.
~0.9–1.3 L/kg
Hepatic via UGT glucuronidation (primarily UGT1A4). Does not undergo significant CYP metabolism. Valproate inhibits lamotrigine glucuronidation (doubles half-life); enzyme inducers (carbamazepine, phenytoin) accelerate metabolism.
Renal (~94%, with ~10% as unchanged lamotrigine and ~76% as 2-N-glucuronide conjugate). Fecal (~2%).
~55%
~30 mL/min (apparent clearance; varies significantly with co-medications)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Lamictal (lamotrigine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Goodwin GM, Haddad PM, Ferrier IN, et al. 2016 — Discontinuation of lamotrigine in bipolar disorder: practical considerations and review (Journal of Psychopharmacology)
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic principle, applied to mood stabilizers) (The Lancet Psychiatry)
- Kessing LV, Hellmund G, Andersen PK 2018 — Lamotrigine for the maintenance treatment of bipolar disorder — a Cochrane systematic review (Cochrane Database of Systematic Reviews)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- International Society for Bipolar Disorders (ISBD) — Specialty society guidance for bipolar maintenance pharmacotherapy
- Deprescribing.org — Clinician-facing deprescribing algorithms
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — mood stabilizer tapering forum — Community archive of lamotrigine discontinuation experiences
- Mad in America — bipolar and mood stabilizer coverage — Independent journalism on lamotrigine and bipolar pharmacology
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of lamotrigine adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.